Neoplasms

Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Neoplasm Metastasis

Skin Neoplasms

Neoplastic Processes

Skin Diseases

All Drugs and Chemicals

Immunomodulating Agents

Adjuvants, Immunologic

Diphencyprone (DPCP)

Vicky K Wong, MS, CCRC

Nicholas Gulati

Nicholas Gulati, MD, PhD

Philip Friedlander, MD, PhD

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Improve Efficacy of PD-1 or PD-L1 Immune Checkpoint Inhibition in the Treatment of Advanced Cancer With Cutaneous Metastases

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Safety and tolerability of dual-therapy DPCP plus immune checkpoint inhibition will be measured as the proportion of subjects with a grade 3 on the Common Terminology Criteria for Adverse Events (CTCAE) criteria for eczema, version 5.0.

Assistant Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases	NCT05481658	Cutaneous Metas...	Diphencyprone (...	18 Years -	Icahn School of Medicine at Mount Sinai
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases	NCT05481658	Cutaneous Metas...	Diphencyprone (...	18 Years -	Icahn School of Medicine at Mount Sinai

Spots Global Cancer Trial Database for diphencyprone (dpcp)